<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480009</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19020221</org_study_id>
    <nct_id>NCT03480009</nct_id>
  </id_info>
  <brief_title>Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion</brief_title>
  <acronym>DexMab</acronym>
  <official_title>Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Study Investigator-Sponsor</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates dextromethorphan as a non-opioid adjunctive medication for pain control&#xD;
      during medication abortion. This is double-blinded, four-arm randomized controlled trial&#xD;
      enrolling 156 women over a period of 9-12 months: Receiving narcotics+dextromethorphan,&#xD;
      narcotics and placebo (microcrystalline cellulose), no narcotics and dextromethorphan and no&#xD;
      narcotics and placebo (microcrystalline cellulose).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medication abortion using mifepristone and misoprostol is common, accounting for nearly&#xD;
      one-third of abortions in the United States in 2014. Although women generally tolerate&#xD;
      medical abortion well, pain and bleeding are common and expected side effects. Up to a&#xD;
      quarter of women rate their pain as severe during their procedure. Pain management for&#xD;
      medical abortion is challenging given that the most acute pain occurs at home rather than&#xD;
      under the supervision of medical professionals. Currently there is insufficient evidence to&#xD;
      recommend an optimal regimen for pain control in medication abortion and there are concerns&#xD;
      surrounding narcotic prescribing and the opiate abuse epidemic. This is a four-arm,&#xD;
      prospective, double-blind, randomized controlled trial comparing dextromethorphan&#xD;
      administration in conjunction with the current standard regimen (NSAIDs and narcotic&#xD;
      medication by request- commonly oxycodone or codeine) to the standard regimen alone. Pain&#xD;
      will be evaluated by analgesia usage and self-reported pain scores. Investigators will also&#xD;
      investigate factors influencing pain and subjective components of the patient narrative.&#xD;
      Ideally, a non-opioid adjunct to NSAIDs or narcotics could be used to control pain and&#xD;
      significantly curtail or avoid opioid use. Investigators seek to test the efficacy and safety&#xD;
      of dextromethorphan as a non-narcotic analgesic for medication abortion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2018</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Worst Pain Measurement Via Numeric Rating Scale (NRS-11)</measure>
    <time_frame>Over 24 hours starting from misoprostol administration</time_frame>
    <description>Self-reported pain measurement via text-messaging system during first 24 hours after misoprostol administration. The scale is from 0 to 10, where 0 represents &quot;no pain&quot; and 10 represents &quot;the worst pain possible&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgesic Usage During Medication Abortion</measure>
    <time_frame>Over 24 hours</time_frame>
    <description>Analgesic usage by study arm for women who received dextromethorphan vs. placebo as adjunct to routine pain management during medication abortion; missing data are for participants who did not take the specified pain medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Scores Via Numeric Rating Scale (NRS-11)</measure>
    <time_frame>Marginal mean pain scores over 24 hours</time_frame>
    <description>Marginal mean pain scores via Numeric Rating Scale (NRS-11) over 24 hours. The scale is from 0 to 10, where 0 represents &quot;no pain&quot; and 10 represents &quot;the worst pain possible&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pain Control Satisfaction Via 4-pt Likert Scale</measure>
    <time_frame>24 hours after misoprostol administration</time_frame>
    <description>Overall satisfaction with pain control, &quot;4&quot; being - &quot;Very good&quot; and &quot;1&quot; being &quot;Very bad&quot;</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Abortion in First Trimester</condition>
  <arm_group>
    <arm_group_label>Dextromethorphan, opted for narcotic prescription</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, opted for narcotic prescription</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Avicel PH101 (Microcrystalline Cellulose NF) and patient opts for narcotics (oxycodone or other standard narcotics)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextromethorphan, declined narcotic prescription</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextromethorphan hydrobromide and patient declines narcotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, declined narcotic prescription</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and patient declines narcotic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan Hydrobromide</intervention_name>
    <description>Dextromethorphan capsule</description>
    <arm_group_label>Dextromethorphan, declined narcotic prescription</arm_group_label>
    <arm_group_label>Dextromethorphan, opted for narcotic prescription</arm_group_label>
    <other_name>Robitussin, Delsym</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avicel PH101 (Microcrystalline Cellulose NF) for Compounding</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo, declined narcotic prescription</arm_group_label>
    <arm_group_label>Placebo, opted for narcotic prescription</arm_group_label>
    <other_name>Avicel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.</description>
    <arm_group_label>Dextromethorphan, opted for narcotic prescription</arm_group_label>
    <arm_group_label>Placebo, opted for narcotic prescription</arm_group_label>
    <other_name>Tylox, Percodan, OxyContin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18 and over&#xD;
&#xD;
          -  Willing to give voluntary consent&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  Eligible for medication abortion per Planned Parenthood of Western Pennsylvania&#xD;
             protocol&#xD;
&#xD;
          -  Self-reported reliable cellular phone access for the duration of study participation&#xD;
&#xD;
          -  Able to receive and reply to a &quot;test&quot; text at time of consent&#xD;
&#xD;
          -  Willing to comply with the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of selective serotonin reuptake inhibitors or monoamine oxidase inhibitors due to&#xD;
             risk of Serotonin Syndrome&#xD;
&#xD;
          -  Allergy to any component of the medication abortion regimen or study drug&#xD;
&#xD;
          -  Has any other condition that, in the opinion of the investigator, would preclude&#xD;
             informed consent, make study participation unsafe, complicate the interpretation of&#xD;
             the study outcome data, or otherwise interfere with achieving the study objectives&#xD;
&#xD;
          -  Anticipated use of dextromethorphan during study period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Must be pregnant to participate</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Family Planning Research, Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Western Pennsylvania</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Penney G. Treatment of pain during medical abortion. Contraception. 2006 Jul;74(1):45-7. Epub 2006 May 6. Review.</citation>
    <PMID>16781260</PMID>
  </reference>
  <reference>
    <citation>Weinbroum AA, Rudick V, Paret G, Ben-Abraham R. The role of dextromethorphan in pain control. Can J Anaesth. 2000 Jun;47(6):585-96. Review.</citation>
    <PMID>10875724</PMID>
  </reference>
  <reference>
    <citation>Ilkjaer S, Nielsen PA, Bach LF, Wernberg M, Dahl JB. The effect of dextromethorphan, alone or in combination with ibuprofen, on postoperative pain after minor gynaecological surgery. Acta Anaesthesiol Scand. 2000 Aug;44(7):873-7.</citation>
    <PMID>10939702</PMID>
  </reference>
  <reference>
    <citation>Christie A, Dagfinrud H, Dale Ø, Schulz T, Hagen KB. Collection of patient-reported outcomes;--text messages on mobile phones provide valid scores and high response rates. BMC Med Res Methodol. 2014 Apr 16;14:52. doi: 10.1186/1471-2288-14-52.</citation>
    <PMID>24735061</PMID>
  </reference>
  <reference>
    <citation>Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol. 2014 Mar;123(3):676-692. doi: 10.1097/01.AOG.0000444454.67279.7d.</citation>
    <PMID>24553166</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <results_first_submitted>June 23, 2020</results_first_submitted>
  <results_first_submitted_qc>July 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2020</results_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Study Investigator-Sponsor</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>medication abortion</keyword>
  <keyword>dextromethorphan</keyword>
  <keyword>pain control</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03480009/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dextromethorphan, Opted for Narcotic Prescription</title>
          <description>Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)&#xD;
Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Opted for Narcotic Prescription</title>
          <description>Avicel PH101 (Microcrystalline Cellulose NF) and patient opts for narcotics (oxycodone or other standard narcotics)&#xD;
Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.</description>
        </group>
        <group group_id="P3">
          <title>Dextromethorphan, Declined Narcotic Prescription</title>
          <description>Dextromethorphan hydrobromide and patient declines narcotic</description>
        </group>
        <group group_id="P4">
          <title>Placebo, Declined Narcotic Prescription</title>
          <description>Avicel PH101 (Microcrystalline Cellulose NF) and patient declines narcotic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Due to unequal distribution during study conduct, the protocol was modified to recruit all participants rather than into study arms. Data were analyzed as: intervention stratified by narcotic prescription status.</population>
      <group_list>
        <group group_id="B1">
          <title>Dextromethorphan, With Narcotic Prescription</title>
          <description>Participants receiving dextromethorphan and a narcotic prescription</description>
        </group>
        <group group_id="B2">
          <title>Placebo, With Narcotic Prescription</title>
          <description>Participants receiving placebo and a narcotic prescription</description>
        </group>
        <group group_id="B3">
          <title>Dextromethorphan, Declined Narcotic Prescription</title>
          <description>Participants receiving dextromethorphan and declined a narcotic prescription</description>
        </group>
        <group group_id="B4">
          <title>Placebo, Declined Narcotic Prescription</title>
          <description>Participants receiving placebo and declined a narcotic prescription</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="156"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.5" spread="5.4"/>
                    <measurement group_id="B2" value="25.8" spread="4.4"/>
                    <measurement group_id="B3" value="27.1" spread="5.0"/>
                    <measurement group_id="B4" value="26.1" spread="5.3"/>
                    <measurement group_id="B5" value="26.6" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race : Non-Hispanic, Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race : Non-Hispanic, White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic, Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic, White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior medication abortion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Worst Pain Measurement Via Numeric Rating Scale (NRS-11)</title>
        <description>Self-reported pain measurement via text-messaging system during first 24 hours after misoprostol administration. The scale is from 0 to 10, where 0 represents &quot;no pain&quot; and 10 represents &quot;the worst pain possible&quot;.</description>
        <time_frame>Over 24 hours starting from misoprostol administration</time_frame>
        <population>Intention to treat population where all participants were analyzed as randomized. Missing worst pain responses were imputed as 10 being the worst pain possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Dextromethorphan, Opted for Narcotic Prescription</title>
            <description>Participants receiving dextromethorphan and opted for a narcotic prescription</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Opted for Narcotic Prescription</title>
            <description>Participants receiving placebo and opted for a narcotic prescription</description>
          </group>
          <group group_id="O3">
            <title>Dextromethorphan, Declined Narcotic Prescription</title>
            <description>Participants receiving dextromethorphan and declined a narcotic prescription</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Declined Narcotic Prescription</title>
            <description>Participants receiving placebo and declined a narcotic prescription</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Pain Measurement Via Numeric Rating Scale (NRS-11)</title>
          <description>Self-reported pain measurement via text-messaging system during first 24 hours after misoprostol administration. The scale is from 0 to 10, where 0 represents &quot;no pain&quot; and 10 represents &quot;the worst pain possible&quot;.</description>
          <population>Intention to treat population where all participants were analyzed as randomized. Missing worst pain responses were imputed as 10 being the worst pain possible.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="6.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="7.0" lower_limit="5.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="7.5" lower_limit="5.5" upper_limit="10.0"/>
                    <measurement group_id="O4" value="6.5" lower_limit="4.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.20</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.20</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Analgesic Usage During Medication Abortion</title>
        <description>Analgesic usage by study arm for women who received dextromethorphan vs. placebo as adjunct to routine pain management during medication abortion; missing data are for participants who did not take the specified pain medication.</description>
        <time_frame>Over 24 hours</time_frame>
        <population>Missing data are for participants who did not take the specified pain medication</population>
        <group_list>
          <group group_id="O1">
            <title>Dextromethorphan, Opted for Narcotic Prescription</title>
            <description>Participants receiving dextromethorphan and opted for a narcotic prescription</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Opted for Narcotic Prescription</title>
            <description>Participants receiving placebo and opted for a narcotic prescription</description>
          </group>
          <group group_id="O3">
            <title>Dextromethorphan, Declined Narcotic Prescription</title>
            <description>Participants receiving dextromethorphan and declined a narcotic prescription</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Declined Narcotic Prescription</title>
            <description>Participants receiving placebo and declined a narcotic prescription</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesic Usage During Medication Abortion</title>
          <description>Analgesic usage by study arm for women who received dextromethorphan vs. placebo as adjunct to routine pain management during medication abortion; missing data are for participants who did not take the specified pain medication.</description>
          <population>Missing data are for participants who did not take the specified pain medication</population>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ibuprofen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="800" lower_limit="400" upper_limit="1200"/>
                    <measurement group_id="O2" value="600" lower_limit="400" upper_limit="1450"/>
                    <measurement group_id="O3" value="800" lower_limit="600" upper_limit="1600"/>
                    <measurement group_id="O4" value="1000" lower_limit="505" upper_limit="1400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9acetaminophen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1000" lower_limit="825" upper_limit="2000"/>
                    <measurement group_id="O2" value="1300" lower_limit="1000" upper_limit="2500"/>
                    <measurement group_id="O3" value="800" lower_limit="600" upper_limit="1600"/>
                    <measurement group_id="O4" value="975" lower_limit="500" upper_limit="2000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>oxycodone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O4" value="15" lower_limit="15" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.81</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>acetaminophen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.24</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>oxycodone</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.54</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.61</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acetaminophen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.24</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Scores Via Numeric Rating Scale (NRS-11)</title>
        <description>Marginal mean pain scores via Numeric Rating Scale (NRS-11) over 24 hours. The scale is from 0 to 10, where 0 represents &quot;no pain&quot; and 10 represents &quot;the worst pain possible&quot;.</description>
        <time_frame>Marginal mean pain scores over 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dextromethorphan, Opted for Narcotic Prescription</title>
            <description>Participants receiving dextromethorphan and opted for a narcotic prescription</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Opted for Narcotic Prescription</title>
            <description>Participants receiving placebo and opted for a narcotic prescription</description>
          </group>
          <group group_id="O3">
            <title>Dextromethorphan, Declined Narcotic Prescription</title>
            <description>Participants receiving dextromethorphan and declined a narcotic prescription</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Declined Narcotic Prescription</title>
            <description>Participants receiving placebo and declined a narcotic prescription</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores Via Numeric Rating Scale (NRS-11)</title>
          <description>Marginal mean pain scores via Numeric Rating Scale (NRS-11) over 24 hours. The scale is from 0 to 10, where 0 represents &quot;no pain&quot; and 10 represents &quot;the worst pain possible&quot;.</description>
          <units>score on a scale (NRS-11)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="2.92"/>
                    <measurement group_id="O2" value="2.96" spread="2.76"/>
                    <measurement group_id="O3" value="2.70" spread="2.95"/>
                    <measurement group_id="O4" value="2.41" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.99</p_value>
            <method>Wald Chi Square</method>
            <method_desc>Wald Chi Square from mixed effects linear regression</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.56</p_value>
            <method>Wald Chi Square</method>
            <method_desc>P-value from Wald chi-square from mixed effects linear regression</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pain Control Satisfaction Via 4-pt Likert Scale</title>
        <description>Overall satisfaction with pain control, &quot;4&quot; being - &quot;Very good&quot; and &quot;1&quot; being &quot;Very bad&quot;</description>
        <time_frame>24 hours after misoprostol administration</time_frame>
        <population>There are missing data for 3 participants in the dextromethorphan group (1 that opted for a narcotic prescription and 2 that declined) and 3 participants in the placebo (opted for narcotic prescription group).</population>
        <group_list>
          <group group_id="O1">
            <title>Dextromethorphan, Opted for Narcotic Prescription</title>
            <description>Participants receiving dextromethorphan and opted for narcotic prescription</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Opted for Narcotic Prescription</title>
            <description>Participants receiving placebo and opted for narcotic prescription</description>
          </group>
          <group group_id="O3">
            <title>Dextromethorphan, Declined Narcotic Prescription</title>
            <description>Participants receiving dextromethorphan and declined narcotic prescription</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Declined Narcotic Prescription</title>
            <description>Participants receiving placebo and declined a narcotic prescription</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pain Control Satisfaction Via 4-pt Likert Scale</title>
          <description>Overall satisfaction with pain control, &quot;4&quot; being - &quot;Very good&quot; and &quot;1&quot; being &quot;Very bad&quot;</description>
          <population>There are missing data for 3 participants in the dextromethorphan group (1 that opted for a narcotic prescription and 2 that declined) and 3 participants in the placebo (opted for narcotic prescription group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.07</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.50</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3-5 days after enrollment</time_frame>
      <desc>Adverse events were collected using text messaging at multiple timepoints (at baseline, misoprostol administration, and 2, 5, 8, and 24 hours after misoprostol) and by phone call 3-5 days later</desc>
      <group_list>
        <group group_id="E1">
          <title>Dextromethorphan, Opted for Narcotic Prescription</title>
          <description>Participants receiving dextromethorphan and opted for a narcotic prescription</description>
        </group>
        <group group_id="E2">
          <title>Placebo, Opted for Narcotic Prescription</title>
          <description>Participants receiving placebo and opted for a narcotic prescription</description>
        </group>
        <group group_id="E3">
          <title>Dextromethorphan, Declined Narcotic Prescription</title>
          <description>Participants receiving dextromethorphan and declined a narcotic prescription</description>
        </group>
        <group group_id="E4">
          <title>Placebo, Declined Narcotic Prescription</title>
          <description>Participants receiving placebo and declined a narcotic prescription</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator, MD MPH</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-641-5496</phone>
      <email>fpr@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

